A liver lesion is any abnormal area of tissue within the liver, ranging from a harmless fluid-filled cyst to a cancerous tumor. The term itself is deliberately broad and does not tell you whether something is dangerous. Most liver lesions discovered on imaging turn out to be benign, often found by accident during a scan ordered for an unrelated reason. But because the liver is also a common site for both primary cancers and cancers that have spread from elsewhere, figuring out exactly what a lesion is matters enormously for deciding what, if anything, to do about it.
How Most Liver Lesions Are Discovered
The majority of liver lesions never cause symptoms. They show up when a doctor orders an abdominal ultrasound, CT scan, or MRI for something else entirely, like investigating abdominal pain, checking on gallstones, or staging a known cancer. This kind of accidental discovery has become far more common as imaging technology has improved and scans have become routine in emergency and outpatient settings. Focal liver lesions found this way are one of the most frequent reasons patients get referred to a liver specialist.1PubMed Central. Focal liver lesions found incidentally
When a lesion turns up unexpectedly, the clinical context shapes the workup. If you have a history of chronic liver disease, hepatitis, heavy alcohol use, or a known cancer somewhere else in the body, a new liver lesion gets treated with more urgency. If you are otherwise healthy and your liver function tests are normal, the odds tilt heavily toward a benign explanation. The American College of Gastroenterology notes that focal liver lesions have become an increasingly common finding, and that clinicians need to be comfortable distinguishing the harmless ones from those requiring action.2PubMed Central. ACG Clinical Guideline: Focal Liver Lesions
Benign Solid Lesions
The three most common benign solid liver lesions are hemangiomas, focal nodular hyperplasia, and hepatic adenomas. They differ in what they are made of, how they behave, and whether they need treatment.
Hemangiomas
Hepatic hemangiomas are the single most common benign liver tumor. They are clusters of blood-filled spaces fed by the hepatic artery and are thought to arise from a vascular malformation, though the exact cause is not fully understood.3PubMed Central. Hepatic hemangioma: What internists need to know Most are small, well-defined, and completely silent. Typical ones range from a few millimeters to about 3 centimeters and do not grow over time. Medium-sized hemangiomas (up to about 10 cm) usually still require nothing more than periodic imaging to confirm stability.4PubMed Central. Hepatic hemangioma -review-
Problems arise mainly with so-called giant hemangiomas, which can reach 10 cm or occasionally well beyond 20 cm. At that size, they can press on surrounding structures, stretch the liver capsule, and cause upper abdominal pain. Less commonly, a very large hemangioma can rupture or cause clotting complications. In symptomatic cases, treatment options include surgical removal (enucleation tends to have fewer complications than removing a whole section of liver), embolization to cut off the blood supply, or radiofrequency ablation.3PubMed Central. Hepatic hemangioma: What internists need to know Fewer than 40% of hemangiomas show any growth at all over time, so a wait-and-watch approach is standard for the vast majority.
Focal Nodular Hyperplasia
Focal nodular hyperplasia (FNH) is the second most common benign solid liver lesion. It is not a true tumor but rather a mass of normal-looking liver cells that have multiplied around an abnormal blood vessel. Current research points to a vascular anomaly that alters the activity of certain growth-signaling genes as the underlying trigger.5PubMed Central. Focal Nodular Hyperplasia: A Comprehensive Review with a Particular Focus on Pathogenesis and Complications FNH is much more common in women, typically turns up in people between their twenties and forties, and almost never causes symptoms or becomes cancerous. It has a characteristic central scar visible on contrast-enhanced MRI, which often makes the diagnosis straightforward without a biopsy. Treatment is virtually never needed.
Hepatic Adenomas
Hepatic adenomas are the benign lesion that demands the most clinical attention because they carry real risks. Unlike hemangiomas and FNH, adenomas can bleed and, in a small percentage of cases, transform into liver cancer. A large multicenter analysis found that about a quarter of adenomas ruptured, with no tumor under 5 cm rupturing. Both increasing size and recent hormone use (within six months) were independently associated with rupture risk.6PubMed. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy
Molecular research has identified multiple subtypes of adenoma, each linked to different risk factors and outcomes. One subtype driven by a specific signaling pathway called sonic hedgehog was associated with obesity and bleeding, while another subtype involving beta-catenin activation was linked to malignant transformation. Overall, about 3% of patients in a large study developed liver cancer from their adenoma.7PubMed. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation Because of these risks, adenomas larger than 5 cm are frequently recommended for surgical removal, and patients are advised to stop oral contraceptives or anabolic steroids if they are using them.
Cystic Lesions
Simple liver cysts are extremely common and almost always harmless. They are fluid-filled sacs lined with a thin layer of cells, often discovered incidentally, and rarely need any treatment. The trouble is that not every cyst is simple. Parasitic cysts caused by the tapeworm Echinococcus (hydatid disease), cystadenomas, and cystic metastases can all mimic the appearance of a simple cyst, especially on basic imaging.
Hydatid cysts deserve special mention because they are clinically significant and can be tricky to distinguish from simple cysts in their early stages, when they appear as a uniform fluid-filled pocket.8PubMed Central. Hepatic Hydatid Cyst Misdiagnosed as Simple Cyst: A Case Report On ultrasound, the combination of imaging features and blood tests for antibodies can achieve strong diagnostic accuracy; one study found that combining ultrasound with immunological testing reached a sensitivity of about 82% and specificity of 100% for differentiating early-stage hydatid cysts from simple cysts.9PubMed Central. Differentiation between hepatic cystic echinococcosis types 1 and simple hepatic cysts MRI with diffusion-weighted imaging can also help: hydatid cysts tend to light up differently from simple cysts because the parasitic fluid has different physical properties.10PubMed. Diffusion-weighted imaging in the differential diagnosis of simple and hydatid cysts of the liver Complicated hydatid cysts typically require surgery.
Liver Abscesses
A liver abscess is a pocket of pus caused by bacterial, parasitic, or (less commonly) fungal infection. The bacterial kind, called a pyogenic liver abscess, most often develops in the setting of biliary tract disease. In a European multicenter study, biliary conditions such as gallstones, cholecystitis, and biliary tract cancers were identified in over half of cases. The most commonly cultured bacterium was E. coli, followed by Streptococcus species and anaerobes.11PubMed Central. Characteristics and management of pyogenic liver abscess A European experience
Treatment centers on intravenous antibiotics, but about two-thirds of patients in that study also needed some form of drainage procedure, most commonly a catheter placed through the skin under imaging guidance. Amoebic liver abscesses, caused by the parasite Entamoeba histolytica, are more common in tropical regions and respond to a different antibiotic regimen. On imaging, an abscess can sometimes look worryingly like a tumor, so clinical context and lab findings are critical for making the right call.
Malignant Liver Lesions
Cancerous liver lesions fall into two broad camps: primary liver cancers that originate in the liver itself and metastases that have spread from a cancer somewhere else in the body. Metastatic disease is actually the more common scenario in many populations, since cancers of the colon, breast, lung, and pancreas frequently seed the liver through the bloodstream.
Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer worldwide. It overwhelmingly arises in livers that are already damaged by cirrhosis, chronic hepatitis B or C infection, heavy alcohol use, or metabolic conditions like fatty liver disease. Screening programs for people at high risk typically rely on ultrasound every six months, sometimes combined with blood tests such as alpha-fetoprotein (AFP). A risk-based screening program in Russia using AFP combined with a newer marker called PIVKA-II detected HCC in about 2% of high-risk patients screened, with half of those caught at an early stage.12Russian Journal of Gastroenterology, Hepatology, Coloproctology. Risk-Based Screening of Hepatocellular Cancer in the Krasnoyarsk Region: The First Results
AFP alone has limitations as a screening tool. Its sensitivity for detecting HCC varies depending on tumor size and the severity of underlying liver disease. For small tumors and early-stage cancers, AFP alone performs poorly, but combining it with other markers like CEA, CA 19-9, and GGT can substantially improve diagnostic accuracy at those early stages.13PubMed Central. Evaluation of high-risk factors and the diagnostic value of alpha-fetoprotein in the stratification of primary liver cancer Meanwhile, AFP tends to be elevated in cirrhosis even without cancer, producing false positives that can cause unnecessary anxiety and further testing.14PubMed. Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis
Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma arises from the cells lining the bile ducts. The intrahepatic form, which develops within the liver, accounts for roughly a third of cholangiocarcinomas. In one large single-institution study, the majority of cases arose without any underlying liver disease, the average tumor measured about 6 cm, and abdominal pain was the most common symptom. About 30% were found incidentally on imaging. Median overall survival was roughly 16 months, reflecting the fact that many patients present with advanced disease.15PubMed Central. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma A systematic review found that about a third of patients had lymph node spread at diagnosis, and the tumors frequently invaded blood vessels and nerves.16JAMA Surgery. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis
Metastatic Lesions
When cancer from the colon, lung, breast, stomach, or pancreas spreads to the liver, the resulting lesions are classified as metastatic, not primary liver cancer. This distinction matters because treatment targets the original cancer’s biology. Colorectal cancer liver metastases are among the most studied and, in selected patients, can sometimes be cured with surgery or a combination of chemotherapy and local treatments.17PubMed Central. Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions For metastases from other cancers, the approach varies widely depending on how many lesions there are, where the original tumor is, and how well it responds to systemic therapy.
How Imaging Sorts Things Out
The initial discovery is usually on ultrasound or a non-contrast CT scan, but characterizing a liver lesion almost always requires contrast-enhanced imaging. On CT and MRI, radiologists evaluate a constellation of features: the size and shape of the lesion, whether it has a wall and how thick that wall is, whether there are internal divisions or solid nodules, any calcifications, and critically, the pattern of how the lesion takes up and washes out contrast dye.18PubMed. Cystic focal liver lesions in the adult: differential CT and MR imaging features Many benign lesions have enhancement patterns so characteristic that a confident diagnosis can be made without ever needing a biopsy. Hemangiomas, for example, have a distinctive pattern of peripheral contrast pooling that fills inward over time, while FNH classically shows a central scar that enhances in delayed phases.
MRI with a liver-specific contrast agent (gadoxetic acid) has become particularly valuable for distinguishing subtle lesions in cirrhotic livers, where the stakes are highest. When imaging alone is not definitive, biopsy becomes an option. Historically, there was concern that sticking a needle into a liver tumor could scatter cancer cells along the needle track. A meta-analysis found that the risk of this “needle tract seeding” is roughly 1%, which is lower than many clinicians assumed.19PubMed Central. Risk of tumour seeding in patients with liver lesions undergoing biopsy with or without concurrent ablation: meta-analysis That finding is gradually shifting practice toward using biopsy more freely when tissue analysis could guide targeted therapy.
Treatment of Malignant Liver Lesions
Treatment for liver cancer depends on the type of cancer, the number and size of lesions, the health of the underlying liver, and the patient’s overall fitness. The options span a wide range.
Surgery and Transplantation
For HCC, surgical removal (resection) and liver transplantation remain the treatments with the best chance of cure. The Milan criteria, developed over two decades ago, define which patients with HCC are eligible for transplant based on tumor size and number. They remain the benchmark, though some centers have adopted expanded criteria to include patients who might still benefit.20PubMed Central. Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review
A meta-analysis comparing resection to transplantation in patients who met the Milan criteria found that transplantation offered better overall survival and a recurrence risk about three times lower than resection. The survival advantage was most pronounced in Western populations and in studies completed before 2010; more recent studies with enhanced follow-up surveillance showed similar overall survival between the two approaches, suggesting that close monitoring after resection can partially close the gap.21PubMed Central. Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients Organ scarcity is the practical barrier: many patients who would benefit from a transplant never receive one.
Locoregional Therapies
When surgery is not feasible, locoregional treatments target the tumor directly while sparing as much healthy liver as possible. Radiofrequency ablation uses heat to destroy small tumors and is often used for HCC lesions under about 3 cm. Transarterial chemoembolization (TACE) delivers chemotherapy directly into the tumor’s blood supply and then blocks the feeding artery, starving the tumor. Radioembolization takes a different approach: tiny radioactive microspheres loaded with yttrium-90 are injected into the hepatic artery and lodge inside the tumor, delivering internal radiation. This technique produces disease control in over 80% of cases and is generally well tolerated, even in patients with portal vein blockage. Its survival outcomes are comparable to TACE for intermediate-stage disease and to the drug sorafenib for advanced-stage HCC.22PubMed. Radioembolization for hepatocellular carcinoma Radioembolization can also serve as a bridge to keep the cancer in check while a patient waits for a transplant or to shrink a tumor enough to make surgery possible.23American Journal of Clinical Oncology. Radioembolization for Hepatocellular Carcinoma
Systemic and Targeted Drug Therapy
For advanced HCC that cannot be treated with surgery or locoregional methods, drug therapy has improved considerably. The combination of atezolizumab (an immunotherapy drug) and bevacizumab (which blocks blood-vessel growth) has become the new first-line standard, outperforming sorafenib, the drug that dominated for over a decade, in both overall survival and time before disease progression.24PubMed Central. Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer Other immunotherapy-plus-targeted-drug combinations are also showing promise, and head-to-head trials comparing them are ongoing.25PubMed Central. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy
Preventing Malignant Transformation
Because the most dangerous liver lesions tend to grow from chronically damaged livers, managing the underlying disease is the single best prevention strategy. For people with chronic hepatitis B or C, antiviral treatment can dramatically reduce the risk of developing HCC. For the growing population of people with non-alcoholic fatty liver disease (NAFLD), lifestyle changes are central: modest weight loss of around 3% of body weight can reduce fat in the liver, but losing roughly 10% or more is needed to reverse the inflammation and scarring (fibrosis) that raise cancer risk.26PubMed Central. Therapies In Non-Alcoholic Steatohepatitis (Nash) Limiting alcohol intake, maintaining a healthy weight, and getting vaccinated against hepatitis B are all straightforward steps that lower the odds of ever needing to deal with a malignant liver lesion.
Liver Lesions in Children
Pediatric liver lesions are a separate world. The liver is the third most common site of abdominal tumors in children, and the types that occur differ sharply from those in adults.27PubMed Central. Pediatric Primary Hepatic Tumors: Diagnostic Considerations In infants, the most common benign tumor is an infantile hemangioma, which often shrinks on its own. Hepatoblastoma, a cancer almost exclusive to children under five, is the most common malignant liver tumor in that age group. Older children and adolescents can develop hepatocellular carcinoma, sometimes in the absence of cirrhosis, and a variant called fibrolamellar carcinoma tends to occur in otherwise healthy teenagers and young adults. The diagnostic approach in children emphasizes age-specific probabilities and tries to minimize radiation exposure from imaging.
AI-Assisted Diagnosis on the Horizon
Artificial intelligence is increasingly being tested as a tool to help radiologists characterize liver lesions. Deep-learning models trained on MRI data have achieved lesion classification accuracy of about 97% in test sets, and when junior radiologists used one such model as a second opinion, their diagnostic accuracy improved by an average of about 5 percentage points and their reading time dropped by roughly 35 seconds per case.28PubMed. An Explainable Deep Learning Model for Focal Liver Lesion Diagnosis Using Multiparametric MRI Another AI model working from contrast-enhanced ultrasound videos achieved accuracy of 85-86% across external test sites, matching senior ultrasound specialists and outperforming junior ones.29PubMed. Contrast-enhanced ultrasound-based AI model for multi-classification of focal liver lesions These tools are not replacing radiologists, but they are reshaping diagnostic workflows and may prove especially useful in settings where experienced liver-imaging specialists are scarce.30PubMed Central. Artificial intelligence in imaging for liver disease diagnosis